Cytokine Therapy of HIV Infection
Development of new therapeutics for human immunodeficiency virus (HIV) infection is one of the most active areas of medical research today. While the use of antiretrovirals such as zidovudine has improved survival, these drugs have not been able to halt the progressive destruction of the immune system that characterizes HIV infection. Thus, any design of a comprehensive therapeutic strategy for HIV disease must focus not only on blocking viral replication, but also on restoring immunocompetence. This review will focus on past and current strategies for using cytokine therapy to achieve these goals.
KeywordsHuman Immunodeficiency Virus Natural Killer Human Immunodeficiency Virus Type Acquire Immunodeficiency Syndrome Cytokine Therapy
Unable to display preview. Download preview PDF.
- 3.Ho DD, Hartshorn KL, Rota TR, et al., Recombinant human interferon alfa-A suppresses HTLV-III replication in vitro, Lancet, 1985;i:602–604.Google Scholar
- 6.deWit R, Schattenkerk JK, Boucher CA, et al., Clinical and virological effects of high-dose recombinant interferon-alpha in disseminated AIDS-related Kaposi’s sarcoma, Lancet, 1988;ii:1218–1222.Google Scholar
- 8.Volberding PA, Mitsuyasu R, Recombinant interferon-alpha in the treatment of acquired immune deficiency syndrome related KS, Seiminars Oncol, 1985; 12: 2–6.Google Scholar
- 14.Kovacs JA, Deyton L, Davey R, et al., Combined zidovudine and interferon-a therapy in patients with Kaposi’s sarcoma and the acquired immunodeficiency syndrome (AIDS), Ann Intern Med, 1989; 111: 280287.Google Scholar
- 15.Edlin BR, Weinstein RA, Whaling SM, et al., Zidovudine-interferon-alpha combination therapy in patients with advanced human immunodeficiency virus type 1 infection: biphasic response of p24 antigen and quantitative polymerase chain reaction, J Infect Dis, 1992; 165: 793–798.PubMedCrossRefGoogle Scholar
- 16.Fisch’ MA, Uttamchandani RB, Resnick L, et al., A phase I study of recombinant human interferon-alpha 2a or human lymphoblastoid interferon-alpha nl and concomitant zidovudine in patients with AIDS-related Kaposi’s sarcoma, J Acquir Immune Defic Syndr, 1991; 4: 1–10.Google Scholar
- 19.Hartshorn K, Neumeyer D, Vogt M, et al., Activity of interferons alpha, beta, and gamma against human immunodeficiency virus replication in vitro, AIDS Res Hum Retroviruses, 1987; 112: 582–589.Google Scholar
- 20.Miles SA, Wang HJ, Cortes E. et al., Beta-interferon therapy in patients with poor-prognosis Kaposi sarcoma related to the acquired immunodeficiency syndrome (AIDS). A phase II trial with preliminary evidence of antiviral activity and low incidence of opportunistic infectio, Ann Intern Med, 1990; 112: 58 2589.Google Scholar
- 27.Ernst M, Kern P, Flad HD, et al., Effects of systemic in vivo interleukin-2 (IL-2) reconstitution in patients with acquired immune deficiency syndrome and AIDS-related complex on phenotypes and functions of peripheral blood mononuclear cells, J Clin Immunol, 1986; 6: 170–181.PubMedCrossRefGoogle Scholar
- 33.Waites L, Fyfe G, Senechek D, et al., Polyethylene glycol modified interleukin-2 (PEG IL-2) therapy in HIV seropositive individuals [abstract no. PuB 7580], In: Program and abstracts: VIII International Conference on AIDS ( Amsterdam ), Congrex Holland BV, 1992.Google Scholar